209 related articles for article (PubMed ID: 25495407)
1. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
4. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
6. Defining risks of taxane neuropathy: insights from randomized clinical trials.
Kudlowitz D; Muggia F
Clin Cancer Res; 2013 Sep; 19(17):4570-7. PubMed ID: 23817688
[TBL] [Abstract][Full Text] [Related]
7. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
8. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
De Iuliis F; Salerno G; Taglieri L; Scarpa S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313
[TBL] [Abstract][Full Text] [Related]
9. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S; La Verde N; Rota S; Casazza G; Montrasio C; Cheli S; Cona MS; Dalu D; Fasola C; Ferrario S; Filipazzi V; Gambaro A; Tosca N; Clementi E
Pharmacogenomics J; 2021 Aug; 21(4):491-497. PubMed ID: 33649523
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
13. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Lin YC; Chang HK; Chen JS; Wang HM; Yang TS; Liaw CC
Jpn J Clin Oncol; 2007 Jan; 37(1):23-9. PubMed ID: 17172351
[TBL] [Abstract][Full Text] [Related]
14. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
16. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
17. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
[TBL] [Abstract][Full Text] [Related]
18. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Tulsyan S; Chaturvedi P; Singh AK; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
Gene; 2014 Jun; 543(1):69-75. PubMed ID: 24704000
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
